Opinion|Videos|November 6, 2024
Nipocalimab and FcRn Inhibitors in Generalized Myasthenia Gravis
Panelists discuss how recent phase 3 trial results for nipocalimab and batoclimab, both neonatal Fc receptor (FcRn) inhibitors, demonstrate efficacy and safety in different generalized myasthenia gravis patient populations, comparing these findings with earlier phase 2 data and evaluating their potential impact on treatment approaches.
Advertisement
Video content above is prompted by the following:
- Phase 3 data of nipocalimab, an FcRn inhibitor, has recently been presented at the European Academy of Neurology and American Association of Neuromuscular and Electrodiagnostic Medicine conferences in 2024. Please review the efficacy and safety data for nipocalimab in different patient populations.
- What do phase 3 results add to phase 2 study findings with nipocalimab?
- What are your thoughts about nipocalimab data for generalized myasthenia gravis (gMG)?
- Please review the recently published data from the phase 3 trial of investigational FcRn inhibitor batoclimab for gMG.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
- Current Challenges and New Opportunities Ahead for Women in Neurology
September 15th 2025
- 2025 Women in Neurology Conference: Educating, Mentoring, and Networking
September 15th 2025
- Expanding the Alzheimer Drug Development Pipeline
September 12th 2025
- Setting Realistic Expectations for Antiamyloid Therapeutics
September 11th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Stem Cells of Secondary Progressive Multiple Sclerosis Drive Increased Proinflammatory T-Cell Activity
2
Insights Into the Neurobiology of Stuttering From 2025 STARS Conference: Shahriar SheikhBahaei, PhD
3
Optimizing Speech and Movement Therapy to Improve Motor and Nonmotor Symptoms of Parkinson Disease: Cynthia Fox, PhD, CCC-SLP
4
Daridorexant Provides Relief for Insomnia in Women During Menopausal Transition
5